<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01219465</url>
  </required_header>
  <id_info>
    <org_study_id>MSCT1DM003</org_study_id>
    <nct_id>NCT01219465</nct_id>
  </id_info>
  <brief_title>Umbilical Cord Mesenchymal Stem Cells Infusion for Initial Type 1 Diabetes Mellitus</brief_title>
  <official_title>Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cells Infusion for Initial Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Qingdao University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Qingdao University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether umbilical cord Mesenchymal Stem Cells of
      treatment for initial type 1 diabetes is safe and effective.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Type 1 diabetes mellitus (T1DM)is characterized by the autoimmune destruction of the
      pancreatic β cells.Patients require multiple daily insulin injections throughout their lives
      as well as close monitoring of their diet and blood sugar levels to prevent complications.
      The investigators hope umbilical cord Mesenchymal Stem Cells could not only address the need
      for β-cell replacement but also control of the autoimmune response to β cells.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>September 2010</start_date>
  <completion_date type="Anticipated">December 2012</completion_date>
  <primary_completion_date type="Anticipated">September 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>C peptide release test</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Exogenous insulin dose</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood glucose</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>glycosylated Hemoglobin A1c</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of severe and documented hypoglycemic events</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunologic reconstitution parameters</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Diabetes Mellitus</condition>
  <condition>Diabetes Mellitus, Type 1</condition>
  <condition>Mesenchymal Stem Cells</condition>
  <condition>Umbilical Cord</condition>
  <arm_group>
    <arm_group_label>umbilical cord mesenchymal stem cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous infusion of ex vivo cultured umbilical cord mesenchymal stem cells</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>umbilical cord mesenchymal stem cells</intervention_name>
    <description>Transfusion of the umbilical cord mesenchymal stem cells (2 x 107 cells) intravenously.</description>
    <arm_group_label>umbilical cord mesenchymal stem cells</arm_group_label>
    <other_name>mesenchymal stem cells</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed diagnosis of type 1 diabetes by ADA criteria less than 9 weeks.

          -  Ability to provide written informed consent from patients or Child guardian.

        Exclusion Criteria:

          -  diabetic ketoacidosis.

          -  evidence of retinopathy at baseline.

          -  Body Mass Index &gt;30.

          -  Severe or acute organ damage.

          -  Infectious diseases, e.g. HIV infection, or hepatitis B or C infection.

          -  Severe psychiatric disorder.

          -  Presence of malignancy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yangang Wang, MD Phd</last_name>
    <role>Study Director</role>
    <affiliation>The Affiliated Hospital of Medical College of Qingdao University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stem Cell Research Center of Medical School Hospital of Qingdao University</name>
      <address>
        <city>Qingdao</city>
        <state>Shandong</state>
        <zip>266003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 12, 2010</study_first_submitted>
  <study_first_submitted_qc>October 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 13, 2010</study_first_posted>
  <last_update_submitted>October 12, 2010</last_update_submitted>
  <last_update_submitted_qc>October 12, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 13, 2010</last_update_posted>
  <responsible_party>
    <name_title>Wang, Yangang MD</name_title>
    <organization>Stem Cell Research Center of Medical School Hospital of Qingdao University</organization>
  </responsible_party>
  <keyword>Diabetes Mellitus</keyword>
  <keyword>Diabetes Mellitus, Type 1</keyword>
  <keyword>mesenchymal stem cells</keyword>
  <keyword>Umbilical cord</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

